CM Hospitalar SA

What it is

Founded in 1996 as Mafra Hospitalar and headquartered in São Paulo/Ribeirão Preto, Viveo operates as Brazil’s largest integrated distributor of hospital equipment and medicines. It sits between drug and device makers on one side and hospitals, clinics, home-care services and health institutions — both public and private — on the other.

After rationalising its portfolio, the company now operates under 10 main brands spanning hospital-product manufacturing, sterile-solution compounding, patient-care platforms, hospital-channel distribution, laboratory and vaccine distribution, and a services arm. It reaches customers through 33 service points and distribution centres spread across Brazil.

Who owns it

Private-equity firm DNA Capital took control in 2016, then brought the company to the B3 stock exchange in August 2021 under the ticker VVEO3. DNA Capital’s funds, together with other members of the controlling group, hold roughly 42% of the company; the remainder is in public circulation, apart from about 2.5–3.0% held by management and treasury.

Among public investors, Modal Asset Management is the largest single holder with about 22% of shares outstanding, followed by DNA Capital-related funds at 16% and Perea Capital at 10%. The EODHD data shows institutional investors collectively hold about 69% of shares, with insiders at roughly 12%.

Who runs it

CEO Leonardo Almeida Byrro has led the company since its IPO. Before Viveo, Byrro was VP of Global Supply Chain at food giant BRF and a partner at Tarpon Investimentos; he also held roles at Cremer, McKinsey, and Anheuser-Busch InBev.

The financial side is led by Frederico Oldani, VP Administrativo Financeiro, with Luiz Augusto Silva serving as Chief Operating Officer. The Board of Directors operates under Novo Mercado governance rules — B3’s highest listing standard — and must include at least 20% independent members.

The money, in plain words

Viveo shifts enormous volumes: yearly sales of R$11.6bn (US$2.3 bn) ($2.26bn) make it one of Brazil’s largest healthcare distributors by revenue. Yet from every real of those sales it keeps less than two-tenths of a cent as profit — a net margin of 0.17% (our calculation), compared with the 2023 level of 3.2% — because FY2024 was a disaster: the company lost R$1.4bn (US$272 mn) ($272m) that year, wiping out equity and loading the balance sheet with stress.

A key driver of the FY2024 loss was a large tax provision tied to a state-tax dispute; Viveo subsequently reversed nearly R$315m (US$61 mn) of that provision after a favourable Supreme Court ruling. Even so, net debt stood at about R$2.8bn (US$545 mn) ($545m) as of late 2025, and management has set a target to refinance upcoming maturities and reduce leverage by mid-2026.

For context, owners’ equity on the balance sheet is R$1.94bn (US$377 mn) ($376.6m), meaning the company earns just R$18m (US$4 mn) on that base — a return on equity of 1.1%, far below what Brazilian government bonds yield.

The gross margin — what remains after paying for the products themselves, before any operating costs — was 14.4% in FY2025 (our calculation), recovering from 11.3% in FY2024. That marks the fourth consecutive quarter of gross-margin improvement year-on-year, a sign the pricing and product mix recovery is real.

What it is doing now

In its most recent reported quarter, Viveo’s cash generation improved nearly 30% year-on-year to R$167m (US$32 mn), with management targeting a leverage ratio of 3.5× by 2026 and planning to refinance debt in Q4 2025 / Q1 2026.

CEO Byrro announced his resignation effective 15 January, with André Clark named to succeed him — the most material leadership change at the company since its IPO and a moment investors will watch closely for any shift in strategy or cost discipline.

What to watch

• CEO transition: André Clark’s first moves on capital allocation and debt refinancing will set the tone for 2026.
• Debt wall: R$2.8bn (US$545 mn) ($545m) in net debt must be refinanced; terms and timing will directly affect whether thin margins translate into anything for shareholders.
• Margin recovery: Four consecutive quarters of gross-margin expansion is encouraging; the test is whether operating costs can be cut fast enough to turn that into meaningful net profit.
• Public-sector exposure: Winning and managing government hospital-supply contracts carries its own working-capital and payment-timing risks that can quickly turn a paper profit into a cash drain.
• Valuation tension: The stock trades at 21× trailing earnings on a 0.17% net margin — the market is pricing a recovery, not the present reality.

This is news, not investment advice.